Argus analyst Jasper Hellweg raised the firm’s price target on Regeneron to $1,170 from $1,060 and keeps a Buy rating on the shares. The company stands to benefit from positive developments over the next 12 months, including potential FDA and European Commission approvals of linvoseltamab as a treatment for relapsed/refractory multiple myeloma and for Dupixent as a treatment for uncontrolled chronic obstructive pulmonary disease, the analyst tells investors in a research note. The firm adds that Regeneron shares appears favorably valued at 24-times projected 2024 earnings, below the peer average of 25-times.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron (NASDAQ:REGN): Is This Stock-Split Contender a Strong Buy?
- Regeneron presents follow-up data from pivotal Phase 1/2 LINKER-MM1 trial
- Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
- REGN, CI, BSX: Which “Strong Buy” Healthcare Stock Is the Best Bet?
- Regeneron price target raised to $1,229 from $1,200 at RBC Capital